GLP-1 race for obesity: Lilly against Novo Nordisk and the direct channel
Competition between Eli Lilly and Novo Nordisk for the GLP-1 obesity drug market shifts from clinical efficacy to distribution: head-to-head results for retatrutide and CagriSema, regulatory approvals in the EU and direct-to-consumer models that bypass pharmacies and telemedicine. Public capital validates the thesis with Lilly at all-time highs and Novo raising forecasts, while marketing litigation and conflicts of interest with Oura expose the regulatory fragility of the channel. It matters because the regulatory and distribution layer defines who captures the margin of a therapeutic category that reconfigures public health, insurance and consumption.
Title, thesis and gravity assessment written by an AI model, without prior human review.
Phase 3 clinical trial of retatrutide shows superiority over Ozempic in weight loss and glycemic control, and the EMA's CHMP backs Lilly's oral pill. Material data TODAY for competitive repositioning in GLP-1, although without final approval or full regulatory disruption.
- Coverage
- 4 feeds · 4 independent publisher groups (corroborated)
- Cross verticals
- Geopolitics, Lifespan & Healthspan, Investing
- Gravity vs. the previous edition
- +17 (55 → 72)
coverage, not accuracy
More: STAT News, El País América, Expansión (MX)
- 15:58
- 17:31
- 18:30
- 11:45
- 14:42
- 17:38
- 14:37
- 11:29
- 16:19
- 15:30
- 19:04
- 22:07
- 10:30
- 18:03
- 0European and Japanese space exploration of the deep solar system
- 82Reconfiguration of private capital in the US healthcare sector
- 82Attacks with AI agents and regulatory response in Asia
- 82Pharmaceutical agreements between China and the West and R&D relocation
- 80Binance security breach and insurer scrutiny of crypto exchanges